USANA Health Sciences, Inc. — Form 10-K Summary
Period note: The request identifies “2020 Q4,” but this filing is the annual report for fiscal 2021, ended January 1, 2022. Fiscal 2020 ended January 2, 2021 and included 53 weeks; fiscal 2021 included 52 weeks.
Business context
USANA develops and sells nutritional, food, personal-care, and skincare products through direct selling in 24 markets. It reported approximately 560,000 active Customers at year-end. China is its largest individual market, representing approximately 42.7% of 2021 net sales; sales outside the United States were 90.7% of consolidated sales. The company’s business depends on independent Associates and is exposed to foreign exchange movements and regulation of direct selling.
Key financial results
| Metric | FY2021 | FY2020 |
|---|---|---|
| Net sales | $1,186.5 million | $1,134.6 million |
| Gross profit / margin | $968.6 million / 81.6% | $925.5 million / 81.6% |
| Operating earnings / margin | $170.2 million / 14.3% | $176.5 million / 15.6% |
| Net earnings / margin | $116.5 million / 9.8% | $124.7 million / 11.0% |
| Diluted EPS | $5.73 | $5.86 |
| Cash from operations | $121.2 million | $160.4 million |
| Cash and cash equivalents at year-end | $239.8 million | $311.9 million |
- Reported sales rose 4.6%, but the filing estimates that favorable currency movements added $53.6 million. On a constant-currency basis, sales declined 0.2%. The extra week in FY2020 is estimated to have added $18.0 million of sales and $3.6 million of net earnings to that comparison year.
- Net earnings fell 6.5%. Management attributed the decline primarily to higher relative operating expenses and a higher effective tax rate. Associate incentives rose to 43.8% of sales from 43.0%; SG&A rose to 23.5% from 23.0%.
- The effective tax rate was 31.7%, compared with 29.9%, reflecting lower U.S. domestic pre-tax earnings and tax settlements.
- Operating cash flow declined by $39.2 million year over year. Cash fell chiefly because of $177.8 million in share repurchases and $12.8 million of capital expenditures.
- There was no outstanding debt at year-end. The revolving credit facility provides $75 million of capacity, with potential increases subject to conditions; it matures in August 2025 and includes EBITDA and leverage covenants.
- Current assets were $365.1 million and current liabilities $160.8 million. Inventory was $98.3 million, up from $90.2 million.
Material changes and operating trends
- Active Customers declined 6.5% to 560,000. Greater China increased 1.2% to 255,000, while Southeast Asia Pacific fell 19.0% to 115,000 and Americas and Europe fell 9.0% to 132,000.
- Greater China sales increased 6.2% reported, but declined 0.3% excluding currency effects. Southeast Asia Pacific sales were nearly flat reported and declined 3.0% excluding currency. North Asia sales rose 13.0% reported and 9.6% excluding currency.
- The company repurchased and retired 1.844 million shares for $177.8 million in FY2021. It had $108.2 million remaining under the authorized repurchase plan at year-end. No cash dividends have been paid.
- Products are predominantly nutritionals, which represented 86% of product sales. The Salt Lake City foods facility was fully operational; the Active Nutrition rollout resumed in Q1 2022 after market delays.
Outlook, risks and contingencies
- No quantified FY2022 revenue or earnings guidance is provided in the supplied filing text. Management’s stated priorities include growing active Customers, digital investments, product development, a focus on China, and business-development opportunities.
- Management expects COVID-19-related disruption to continue affecting sales activity, events, supply availability, shipping, and costs during 2022. It described liquidity as strong and expects to fund operations with cash generated from operations.
- Management said inflationary pressures were beginning to raise costs and were expected to weigh negatively on FY2022. Freight expense also pressured FY2021 gross profit, partly offset by favorable currency and lower scrap charges.
- China presents a significant regulatory and concentration risk. BabyCare’s business model and compensation plan have not been approved by the Chinese government; direct-selling license approvals remain suspended, and BabyCare has licenses in only certain provinces and municipalities. The filing describes prior government warnings and fines involving BabyCare or its distributors.
- Other material risks include direct-selling and Associate compliance, possible changes in regulation or independent-contractor status, foreign exchange and U.S.–China tensions, product and advertising regulation, supply-chain disruptions, cybersecurity and privacy, and the ability to retain Associates and Customers.
- The company disclosed ordinary-course litigation and other contingencies; management did not believe any current matter, individually or collectively, would materially adversely affect financial condition, liquidity, or results. Certain contingencies could not be estimated. Contractual obligations totaled $50.9 million, including $18.0 million of operating leases.
- KPMG issued an unqualified opinion on the financial statements and reported effective internal control over financial reporting. Inventory valuation was identified as a critical audit matter, focused on estimates of future demand for excess or slow-moving inventory.
Important facts for investors to verify
- Reconcile the reported sales increase with the 53-week FY2020 comparison and the substantial favorable currency impact; assess underlying constant-currency demand.
- Track active Customer trends by market, especially Southeast Asia Pacific and China, and the relationship between customer counts and sales.
- Review whether operating expenses, tax rate, inflation, freight, and supply-chain costs pressure margins and earnings in FY2022.
- Monitor China regulatory developments, direct-selling licenses, and whether BabyCare’s operating model remains viable under local enforcement.
- Assess cash generation after buybacks, inventory investment, and capital spending, and confirm compliance with credit-facility covenants.
- Review the inventory valuation assumptions highlighted by the auditor, including forecast demand, product shelf life, and slow-moving or non-conforming stock.